HR-7994-119
Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
Sponsored by Raul Ruiz (D-CA)
What it does
This bill would create a competitive federal grant program run by HHS to help public school districts and private K-12 schools purchase FDA-approved opioid overdose reversal drugs (such as naloxone) and develop related emergency response and CPR/drug-education programming. It would also require schools receiving federal funds to report any distribution of these reversal drugs to two federal/regional overdose-tracking databases (NEMSIS and ODMAP).
Who benefits
Students, staff, and families in schools that receive grants, particularly in cities and counties with high opioid overdose rates, who would gain access to overdose reversal drugs and emergency training. School nurses and administrators who currently lack resources to stock these drugs. Public health agencies and researchers who would gain more complete overdose data through NEMSIS and ODMAP reporting.
Who is hurt
Schools that do not receive a grant but must still comply with reporting requirements if they distribute reversal drugs, creating an administrative burden without funding support. Private schools and local educational agencies must divert staff time to develop emergency response plans and comply with federal reporting, and school districts in lower-overdose areas may be deprioritized for funding despite local need. Student and family privacy advocates may be concerned about data reported to federal/regional information systems.
Supporters argue
Supporters argue that opioid overdoses, including from fentanyl, increasingly affect teenagers and school communities, and that schools currently lack funding to stock reversal drugs or train staff to respond. They contend that requiring standardized reporting to NEMSIS and ODMAP would give public health officials better real-time data to direct resources to the hardest-hit communities, mirroring existing overdose-tracking infrastructure used by emergency medical services.
Opponents argue
Opponents argue that mandatory reporting to federal and regional drug-tracking databases could expose sensitive student information without clear privacy safeguards or parental consent provisions, and that the reporting mandate applies to all schools receiving federal funds regardless of whether they receive a grant, creating an unfunded compliance burden. They contend that competitive, one-year grants create inconsistent access, potentially leaving under-resourced districts without reversal drugs after the initial funding period ends.
Constitutional context
Congress is exercising its Spending Clause authority (Art. I, §8, cl. 1) by attaching grant conditions and reporting mandates to schools that receive federal funds, an approach whose limits were addressed in South Dakota v. Dole (1987). The reporting requirement to federal information systems also raises student privacy considerations analogous to those addressed by FERPA, though the bill does not itself amend that statute.
Checks and balances
Congress creates the grant program and reporting mandate by statute; HHS and the Department of Education implement and administer it through regulations and grant conditions, with Congress retaining oversight through required annual reports.
Historical precedent
Federal grant programs conditioning school funding on health and safety measures, such as Substance Abuse and Mental Health Services Administration grants for opioid response, provide a general model, though no directly identical prior mandate for school-based reversal drug reporting exists.